Global /South Korea /Healthcare /Biotechnology /476060

Onconic Therapeutics Inc.

476060

• KRX: 476060 • Delayed

21,250KRW -3%

13.62 USD

As of 8 June 2026, Onconic Therapeutics Inc. has a market cap of $641.33M USD, ranking #13503 globally and #388 in South Korea. It ranks #1216 in the Healthcare sector, and #224 in the Biotechnology industry.

Global Rank

13503

Country Rank

388

Sector Rank

1216

Industry Rank

224

Key Stats

Market Cap

$641.33MUSD

983.04B KRW

Enterprise Value

$596.46MUSD

930.43B KRW

Revenue (TTM)

$34.83MUSD

53.39B KRW

EBITDA (TTM)

$8.43MUSD

13.15B KRW

Net Income (TTM)

$10.3MUSD

15.78B KRW

EBITDA Margin

25%

Profit Margin

30%

PE Ratio

62.3

PS Ratio

18.4

PB Ratio

13.6

EV/EBITDA

70.8

Company Profile

Country (HQ)

South Korea

Sector

Healthcare

Industry

Biotechnology

CEO

John Kim open_in_new

Founded

2020

Website

onconic.co.kr open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-3%	-0.9%	-5%	13%	15%	12%	315%	261%	261%

News

Markets

Exchange	Ticker	Price	Quotes
Korea Exchange (KRX) MIC: XKRX PRIMARY	476060 온코닉테라퓨틱스 주식회사 ISIN: KR7476060009 Shares Out.: Shares Outstanding: 45.408M¹ Shares Float: 20.439M² TV: TradingView: KRX: 476060 SA: Stock Analysis: KRX: 476060 YF: Yahoo Finance: 476060.KS GF: Google Finance: KRX: 476060 BA: Barron's: 476060 MS: Morningstar: XKRX: 476060	21,250 KRW	TV: TradingView: KRX: 476060 SA: Stock Analysis: KRX: 476060 YF: Yahoo Finance: 476060.KS GF: Google Finance: KRX: 476060 BA: Barron's: 476060 MS: Morningstar: XKRX: 476060

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Onconic Therapeutics Inc.

Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer. The company was founded in 2020 and is based in Seoul, South Korea.

Similar Companies

Industry: Biotechnology (South Korea)

Name	Market Cap (USD) diff.	PE	Country
Samsung Biologics Co.,Ltd. KRX: 207940	$44.48B 68.19T KRW 7K%	35.5	South Korea
Celltrion, Inc. KRX: 068270	$27.89B 42.76T KRW 4K%	43.8	South Korea
ALTEOGEN Inc. KRX: 196170	$13.27B 20.33T KRW 2K%	146.6	South Korea
HLB Co., Ltd. KRX: 028300	$5.46B 8.37T KRW 752%	-	South Korea
Peptron, Inc. KRX: 087010	$3.96B 6.07T KRW 518%	-	South Korea
SK bioscience Co.,Ltd. KRX: 302440	$2.23B 3.42T KRW 248%	-	South Korea

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 28K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 25K%	19.0	United States
argenx SE EBR: ARGX	$48.08B 41.39B EUR 7K%	39.9	Netherlands
CSL Ltd. ASX: CSL	$43.01B 60.27B AUD 7K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.72B 33.71B CHF 7K%	37.2	Switzerland
Natera, Inc. NASDAQ: NTRA	$27.6B 4K%	-	United States

chevron_leftBack